We are live on ! Find out more
PRAX icon

Praxis Precision Medicines

150 hedge funds and large institutions have $889M invested in Praxis Precision Medicines in 2025 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 47 increasing their positions, 53 reducing their positions, and 45 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 77 (0)

0.2% less ownership

Funds ownership: 116.53%116.33% (-0.2%)

7% less funds holding

Funds holding: 162150 (-12)

11% less repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 53

22% less call options, than puts

Call options by funds: $17.8M | Put options by funds: $22.8M

27% less first-time investments, than exits

New positions opened: 33 | Existing positions closed: 45

47% less capital invested

Capital invested by funds: $1.67B → $889M (-$782M)

Holders
150
Holders Change
-12
Holders Change %
-7.41%
% of All Funds
2.01%
Holding in Top 10
7
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.09%
New
33
Increased
47
Reduced
53
Closed
45
Calls
$17.8M
Puts
$22.8M
Net Calls
-$5.03M
Net Calls Change
-$50.5M
Name Holding Trade Value Shares
Change
Change in
Stake
CAM
1
Cormorant Asset Management
Massachusetts
$66.1M +$3.23M +51,781 +3%
Adage Capital Partners
2
Adage Capital Partners
Massachusetts
$66M +$71.1M +1,137,748 +188%
Janus Henderson Group
3
Janus Henderson Group
United Kingdom
$58.3M +$36M +576,913 +62%
BlackRock
4
BlackRock
New York
$53.7M -$2.84M -45,510 -3%
Morgan Stanley
5
Morgan Stanley
New York
$46M +$3.13M +50,143 +4%
SCM
6
Soleus Capital Management
Connecticut
$43.2M +$56M +896,200 +368%
T. Rowe Price Associates
7
T. Rowe Price Associates
Maryland
$41.5M -$7.04M -112,797 -9%
Vanguard Group
8
Vanguard Group
Pennsylvania
$41.2M +$1.46M +23,381 +2%
VA
9
VR Adviser
New York
$37.5M
PA
10
Perceptive Advisors
New York
$37.1M -$21.8M -348,841 -26%
Capital Research Global Investors
11
Capital Research Global Investors
California
$32.3M -$8.73M -139,823 -14%
State Street
12
State Street
Massachusetts
$27.9M -$1.97M -31,616 -4%
DM
13
Deerfield Management
New York
$23.5M +$38.7M +619,931 New
Assenagon Asset Management
14
Assenagon Asset Management
Luxembourg
$19.2M -$3.23M -51,682 -9%
DCM
15
Driehaus Capital Management
Illinois
$18.2M +$19.8M +316,686 +192%
Bank of America
16
Bank of America
North Carolina
$17.4M +$28.4M +455,203 +8,270%
Geode Capital Management
17
Geode Capital Management
Massachusetts
$15.8M +$706K +11,305 +3%
Balyasny Asset Management
18
Balyasny Asset Management
Illinois
$15.3M +$25.2M +403,003 New
CIBC Asset Management
19
CIBC Asset Management
Ontario, Canada
$14.7M +$1.37M +22,003 +6%
Point72 Asset Management
20
Point72 Asset Management
Connecticut
$12.6M -$11.7M -187,739 -36%
BBA
21
Baker Bros. Advisors
New York
$12.6M
Franklin Resources
22
Franklin Resources
California
$11.9M -$4.73M -75,708 -19%
Verition Fund Management
23
Verition Fund Management
Connecticut
$7.56M -$16.5M -264,851 -57%
UBS Group
24
UBS Group
Switzerland
$7.31M +$4.54M +72,642 +60%
VCIM
25
Velan Capital Investment Management
Georgia
$7.01M -$7.18M -115,000 -38%

PRAX Hedge Fund Activity: Q1 2025 in Review

150 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Praxis Precision Medicines (PRAX) for Q1 2025, worth a combined $889M — down 47% from $1.67B a quarter earlier.

Sellers outnumbered buyers: 45 funds closed out of PRAX and 33 opened new positions — a net loss of 12 holders — while 53 trimmed existing stakes and 47 added.

The largest buyer was Adage Capital Partners, adding an estimated $71.1M. The largest seller was RA Capital Management, exiting entirely with an estimated $58.6M sold.

  • 150 institutional investors held Praxis Precision Medicines (PRAX) as of Q1 2025, down from 162 in Q4 2024.
  • Funds reported $889M of Praxis Precision Medicines stock for Q1 2025, down 47% quarter-over-quarter.
  • 33 funds opened new Praxis Precision Medicines positions in Q1 2025 and 45 closed out, a net change of -12 holders.
  • The largest Praxis Precision Medicines buyer in Q1 2025 was Adage Capital Partners, an estimated $71.1M added.
  • The largest Praxis Precision Medicines seller in Q1 2025 was RA Capital Management, an estimated $58.6M sold.

Based on aggregated 13F filings for Q1 2025.